GEN-AFRICA: Genetic Determinants of Kidney Disease in People of African Ancestry With HIV

Sponsor
King's College Hospital NHS Trust (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05685810
Collaborator
Guy's and St Thomas' NHS Foundation Trust (Other), St George's University Hospitals NHS Foundation Trust (Other), Lewisham and Greenwich NHS Trust (Other), Royal Free Hospital NHS Foundation Trust (Other), Central and North West London NHS Foundation Trust (Other), Barts & The London NHS Trust (Other), Chelsea and Westminster Hospital NHS Foundation Trust (Other), Imperial College Healthcare NHS Trust (Other), North Middlesex University Hospital NHS Trust (Other), Brighton and Sussex University Hospitals NHS Trust (Other), The Leeds Teaching Hospitals NHS Trust (Other), Manchester University NHS Foundation Trust (Other), Newcastle-upon-Tyne Hospitals NHS Trust (Other), South Tees Hospitals NHS Foundation Trust (Other), Africa Advocacy Foundation (Other), Vanderbilt University (Other), University of Cape Town (Other), University of Pennsylvania (Other), Medical Research Council (Other), Guy's and St. Thomas' Charity (Other), British HIV Association (Other), Gilead Sciences (Industry)
3,029
1
141
21.5

Study Details

Study Description

Brief Summary

Black ethnicity is a major risk factor for chronic kidney disease [CKD] in people with HIV infection, suggesting that genetic factors are an important determinant of kidney disease progression in this population. The Gen-Africa study was established in 2018 to allow the study of genetic and clinical risk factors for CKD in people with HIV in the UK. Just over 3000 people across 15 sites were enrolled between May 2018 and January 2020. Demographic and clinical information was collected, and biological samples (buffy coats, plasma and urine) obtained. Cross-sectional analyses have revealed that participants of West-African ancestry are at higher risk of CKD and end-stage kidney disease [ESKD], and that genetic variants in the apolipoprotein L1 (APOL1) gene and sickle cell trait (SCT) are predictors of CKD and ESKD. The pathogenesis of APOL1- and SCT-associated CKD is incompletely understood, and additional, longitudinal data will be collected to improve understanding of the contribution of demographic, traditional CKD (diabetes, hypertension, obesity/metabolic syndrome, cardiovascular disease) and HIV (immuno-virological and hepatitis B/C co-infection status, antiretroviral medications) risk factors as well as additional genetic and epigenetic markers.

Detailed Description

At enrolment, just over 3,000 people of (self-identified) back ethnicity provided informed consent, a blood and urine sample, weight, height, and blood pressure measurements, and completed a short questionnaire about your health issues and lifestyle factors. HIV treatment history, including most recent and nadir CD4 count and HIV viral load, viral hepatitis status and kidney function measurements were recorded. Records for about 2,350 participants have been successfully linked to the United Kingdom Collaborative HIV Cohort (UK CHIC) which has collected data (demographics, clinical and laboratory parameters) on people with HIV since 1998 at selected clinics in the United Kingdom.

Several GEN-AFRICA sub-studies (CKD-AFRICA, Coronavirus disease (CoV)-AFRICA, Ob-AFRICA) have been conducted or are being planned. Each of these studies has received, or will be submitted for, regulatory approval. The studies have allowed or will allow collection of more detailed clinical information, additional biological samples, and/or through linkage with electronic clinical records, collection of longitudinal data on HIV (CD4, HIV viral load, AIDS-defining illnesses, and details of antiretroviral therapy), comorbidities (diabetes, hypertension, kidney disease, cardiovascular events), measurements such as blood pressure and weight, and results of blood tests including measures of kidney function performed as part of clinical monitoring.

Data collected as part of the GEN-AFRICA study / sub-studies are stored at King's College Hospital under their GEN-AFRICA/CKD-AFRICA/CoV-AFRICA/Ob-AFRICA study identifiers (ID). Samples collected as part of these protocols are labeled by study ID and stored in the James Black Building, King's College London, London, UK, in compliance with human tissue act (HTA) standards. Prof. Frank post is the custodian of the data and samples and will be responsible for ensuring all study activity is compliant with relevant data protection and other policies.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
3029 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Genetic and Clinical Determinants of Cardiovascular Disease, Diabetes, Kidney Disease and Obesity in People of African Ancestry With HIV
Actual Study Start Date :
May 1, 2018
Actual Primary Completion Date :
Jan 31, 2020
Anticipated Study Completion Date :
Jan 31, 2030

Outcome Measures

Primary Outcome Measures

  1. Kidney disease [2018-2030]

    Incidence and predictors of end-stage kidney disease, chronic kidney disease, HIVAN, focal and segmental glomerulosclerosis (FSGS), tenofovir disoproxil fumarate (TDF)-associated kidney injury.

Secondary Outcome Measures

  1. Coronavirus disease (COVID-19) [2020-2023]

    Incidence and clinical and genetic determinants of COVID-19

  2. Multi-morbidity [2019-2023]

    Clinical and social determinants of multi-morbidity

  3. Weight change [2013-2024]

    Weight change in relation to antiretroviral exposures

  4. Obesity [2013-2024]

    Incidence of obesity in relation to antiretroviral exposures

  5. Dysglycaemia [2019-2023]

    Relationship between fasting blood glucose/HbA1c and waist circumference/BMI

  6. Insulin resistance [2019-2023]

    Relationship between fasting blood glucose/HbA1c, insulin/C-peptide, and waist circumference/BMI

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • HIV positive

  • Black ethnicity (self-identified)

  • Informed consent

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 King's College Hospital NHS Foundation Trust London United Kingdom SE5 9RJ

Sponsors and Collaborators

  • King's College Hospital NHS Trust
  • Guy's and St Thomas' NHS Foundation Trust
  • St George's University Hospitals NHS Foundation Trust
  • Lewisham and Greenwich NHS Trust
  • Royal Free Hospital NHS Foundation Trust
  • Central and North West London NHS Foundation Trust
  • Barts & The London NHS Trust
  • Chelsea and Westminster Hospital NHS Foundation Trust
  • Imperial College Healthcare NHS Trust
  • North Middlesex University Hospital NHS Trust
  • Brighton and Sussex University Hospitals NHS Trust
  • The Leeds Teaching Hospitals NHS Trust
  • Manchester University NHS Foundation Trust
  • Newcastle-upon-Tyne Hospitals NHS Trust
  • South Tees Hospitals NHS Foundation Trust
  • Africa Advocacy Foundation
  • Vanderbilt University
  • University of Cape Town
  • University of Pennsylvania
  • Medical Research Council
  • Guy's and St. Thomas' Charity
  • British HIV Association
  • Gilead Sciences

Investigators

  • Principal Investigator: Frank A Post, King's College Hospital NHS Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
King's College Hospital NHS Trust
ClinicalTrials.gov Identifier:
NCT05685810
Other Study ID Numbers:
  • 239895
First Posted:
Jan 17, 2023
Last Update Posted:
Jan 17, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 17, 2023